- |||||||||| NKG2D CAR-NK cells / Chongqing Sidemu Biotechnology Technology
Journal: NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma. (Pubmed Central) - Feb 3, 2022
Overall, these results demonstrate that it is feasible to modify autologous NKAE cells from MM patients to safely express a NKG2D-CAR. Additionally, autologous CAR-NKAE cells display enhanced antimyeloma activity demonstrating that they could be an effective strategy against MM supporting the development of NKG2D-CAR-NK-cell therapy for MM.
- |||||||||| NKG2D-ACE2 CAR-NK cells / Chongqing Sidemu Biotechnology Technology, ACE2 CAR-NK cells / Chongqing Sidemu Biotechnology Technology
Trial completion date, Trial primary completion date: A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells for Therapy of COVID-19 (clinicaltrials.gov) - Nov 16, 2020
P1/2, N=90, Recruiting,
Our study further illustrates the feasibility of using the piggyBac non-viral platform as an efficient and cost-effective way for CAR-NK cell manufacturing. Trial completion date: Sep 2020 --> Aug 2022 | Trial primary completion date: May 2020 --> Feb 2022
|
